Brazilian leader Lula hospitalized with inner ear ailment, then released
Brazil's President Luiz Inacio Lula da Silva attends a joint press conference with Chinese President Xi Jinping (not pictured) at the Great Hall of the People in Beijing, China, Tuesday, May 13, 2025. (Tingshu Wang/Pool Photo via AP)
RIO DE JANEIRO — Brazil's President Luiz Inácio Lula da Silva was diagnosed with labyrinthitis Monday after suffering from vertigo, hospital officials said. The 79-year-old leftist leader has already returned to the country's presidential residence, where he is resting.
The Sirio-Libanes Hospital said in a statement that Lula underwent imaging and blood tests, and its results came within normal limits. Labyrinthitis is an inflammation of the labyrinth in the inner ear, which is responsible for hearing and balance.
The health scare adds to Lula's recent medical worries, which are also part of his allies' concerns ahead of his likely bid for reelection next year.
The most serious is a fall he had in the bathroom of the presidential residence in Brasília on Oct. 19. Almost two months later, he was transferred to São Paulo for surgery after suffering headaches caused by new a bleeding in his head. He was discharged Dec. 15.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
43 minutes ago
- CTV News
Max Domi opens up about his life with diabetes on and off the ice
Max Domi opens up about his Type 1 Diabetes diagnosis at age 12, shares advice for kids, talks tech advances, and his book.
National Post
2 hours ago
- National Post
Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform
Article content BEIJING — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315) today announced that the key technology of its independently developed RenMab™ fully human antibody mouse platform has been granted an invention patent by the Japan Patent Office (JPO). This milestone marks a significant step in strengthening the global intellectual property portfolio of the RenMice ® fully human antibody platform family. It underscores the continued advancement of Biocytogen's comprehensive global patent strategy and highlights the innovation and international recognition of the company's proprietary technologies. Article content RenMab™ mice are a core member of Biocytogen's independently developed RenMice ® fully human antibody discovery platform family. Using Biocytogen's proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCE ®) technology, the complete repertoire of murine immunoglobulin heavy chain and light chain variable region genes was precisely replaced in situ with their human counterparts. As a result, RenMab mice have the full repertoire of human antibody heavy chain VDJ and light chain VJ genes. It retains the ability to mount robust immune responses against diverse antigens, comparable to wild-type mice, and can generate fully human antibodies with native-like diversity, significantly improving the efficiency and success rate of discovering high-potential therapeutic candidates. Importantly, antibodies derived from RenMab mice require no additional humanization, effectively minimizing immunogenicity risks and streamlining the antibody drug development process. Article content With distinct advantages in discovering fully human antibodies and TCRs with low immunogenicity, high diversity, favorable affinity, and excellent physicochemical properties, Biocytogen's RenMice platform series (RenMab™/RenLite ® /RenNano ® /RenTCR-mimic™/RenTCR™) has gained widespread recognition in the global biotech and biopharmaceutical industry. Licensing agreements have been established with 20+ companies, including Merck KGaA, Darmstadt, Germany, Janssen/ Johnson & Johnson, and BeiGene. Leveraging the RenMice platform, the RenBiologics™ program has generated over 1,000,000 fully human antibody sequences and numerous high-potential preclinical candidates against more than 1,000 therapeutic targets. As of December 31, 2024, approximately 200 agreements encompassing therapeutic antibody co-development, out-licensing, and asset transfers have been executed, highlighting the RenMice platform's strong global competitiveness and significant commercial value. Article content With its sustained independent research and cutting-edge technological innovation capabilities, Biocytogen has been actively advancing its global patent portfolio and key technology protections for the RenMice ® platform. To date, the RenMice platform has secured patent grants in nearly 10 countries, including the U.S., China, and Japan, while nearly 40 patent applications are under examination across 15 countries and regions. With the steady progress of the global patent strategy, additional patent grants are anticipated in the near term. This strong intellectual property protection framework will continue to deliver reliable assurance to Biocytogen's partners worldwide. Article content About Biocytogen Article content Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice ® (RenMab™/ RenLite ® / RenNano ® / RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice ® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit Article content Article content Article content Contacts Article content Biocytogen Contacts Article content Article content Antibody assets and platforms: Article content Article content Article content
CTV News
3 hours ago
- CTV News
N.S. woman who survived five strokes shares the importance of knowing the signs
Crystal Garrett speaks with a stroke survivor about the importance of knowing the signs. A Nova Scotia woman is sharing her story during Stroke Awareness Month in an effort to bust some myths and share some key information that could save lives. One of the misconceptions about strokes is they only happen to older people, but Mandy Grace experienced them when she was just 38. Grace says, while it happened two years ago, it feels almost like yesterday. She woke up a little bit early that day and didn't feel right. 'Something was off. I tried to stand up and I wasn't really able to get out of bed. My dog heard me, thought it was go time, so he came running. I couldn't speak to him or reach out and touch him and I immediately was just like, 'Oh my goodness, what is happening to me?' I didn't really know what to do next,' she told CTV Morning Live's Crystal Garrett. Mandy Grace Mandy Grace is pictured during an interview with CTV Morning Live Atlantic. Grace says she has since learned 911 can find your location, even on a mobile device. However, at the time, she called her best friend who luckily answered her phone and was at her house in 10 minutes taking control of the situation and calling 911. 'Because the quicker you can get treatment, the quicker the response is and the more likely it is that you'll have a good outcome,' Grace says. 'The morning after I was admitted to hospital, a scan showed that I had had five strokes, and I was in hospital for about two weeks.' Grace considered herself a healthy person with no known stroke risks. 'I didn't know there were stroke risks that weren't smoking or high blood pressure. One of the indicators for stroke is actually congenital heart disease and it turned out, little known to me, I had a congenital heart defect that allowed a blood clot to pass into my brain, but I'd been living 38 years without it and I thought I was healthy, but sometimes health is not necessarily what you think it is,' she says. Grace was showing some of the FAST signs, which the Heart and Stroke Foundation shares in an effort to save lives: Face – is it drooping? Arms – can you raise both? Speech – is it slurred or jumbled? Time to call 9-1-1 right away. Heart & Stroke FAST campaign In 2014 Heart & Stroke launched the FAST campaign to help Canadians recognize and remember the most common signs of stroke. (Heart & Stroke) 'If you are in any doubt, or if you see someone that you think might be experiencing signs of stroke, call 911. Lifesaving treatment begins literally the minute you dial and there's no downside. Call,' she says. Grace adds sometimes stroke symptoms in younger patients are attributed to something else. 'Some of the things that happened to me as well, some issues with my vision, the balance, the dizziness, the headache – those are not what you think of when you hear stroke necessarily. FAST are the most common signs and the ones that are most likely to be caused only by stroke, but there certainly are other symptoms and the more awareness the better the outcomes are going to be for us,' she says. Grace considers herself fortunate to have as full of a recovery as she'd had. 'I'm back to work full time, I actually coach at Orangetheory Fitness, I'm very active,' she says. 'But when I'm fatigued I do still have some speech deficits, I still struggle with kind of that brain fog and that cognitive fatigue, but overall I'm incredibly lucky to have recovered as well as I have.' For more Nova Scotia news, visit our dedicated provincial page
